Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2375]

Use of platform studies for the evaluation of innovative combinations in solid...

Dr Elizabeth Pease - AstraZeneca, UK

Use of platform studies for the evaluation of innovative combinations in solid tumours and haematologic malignancies ( Dr Elizabeth Pease - AstraZeneca, UK )

Implementing national cancer control plans

Dr Eduardo Cazap and Dr Lisa Stevens

Implementing national cancer control plans ( Dr Eduardo Cazap and Dr Lisa Stevens )

Getting high level care to low and middle income countries

Dr Eduardo Cazap, Dr Clifford Hudis

Getting high level care to low and middle income countries ( Dr Eduardo Cazap, Dr Clifford Hudis )

Tackling the increase in cancer cases worldwide

Dr Eduardo Cazap and Prof Tezer Kutluk

Tackling the increase in cancer cases worldwide ( Dr Eduardo Cazap and Prof Tezer Kutluk )

How will ASCO combat cancer disparities?

Dr Eduardo Cazap, Dr Richard Schilsky

How will ASCO combat cancer disparities? ( Dr Eduardo Cazap, Dr Richard Schilsky )

Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL

Prof Max Topp - University of Würzburg, Würzburg, Germany

$Dose escalation of REGN1979 in patients with relapsed and refractory B-NHL ( Prof Max Topp - University of Würzburg, Würzburg, Germany )$

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T...

Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany

CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy ( Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany )

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy...

Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China

Controlling CRS-related coagulopathy improves the safety of CAR T-cell therapy for MM ( Dr Heng Mei - Huazhong University of Science and Technology, Wuhan, China )

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

ICARIA results: Treating RRMM patients with isatuximab, pomalidomide and low-dose dexamethasone ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )

HORIZON update: Using melflufen to treat RRMM patients refractory to...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

$HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )$

CD33 T cell recruiting antibody constructs for treatment of relapsed refractory...

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

$CD33 T cell recruiting antibody constructs for treatment of relapsed refractory AML ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )$

Targeted treatment of AML using T cell recruiting antibody constructs

Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany

Targeted treatment of AML using T cell recruiting antibody constructs ( Prof Marion Subklewe - LMU Hospital Munich, Munich, Germany )

More from ecancer